JP7824938B2 - Tyk2阻害剤およびその使用 - Google Patents

Tyk2阻害剤およびその使用

Info

Publication number
JP7824938B2
JP7824938B2 JP2023517268A JP2023517268A JP7824938B2 JP 7824938 B2 JP7824938 B2 JP 7824938B2 JP 2023517268 A JP2023517268 A JP 2023517268A JP 2023517268 A JP2023517268 A JP 2023517268A JP 7824938 B2 JP7824938 B2 JP 7824938B2
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
stereoisomer
acceptable salt
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023517268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541203A5 (https=
JP2023541203A (ja
JPWO2022060973A5 (https=
Inventor
ジン,ボアン
ドン,チン
フン,ジーン
Original Assignee
アルミス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルミス インコーポレイテッド filed Critical アルミス インコーポレイテッド
Publication of JP2023541203A publication Critical patent/JP2023541203A/ja
Publication of JP2023541203A5 publication Critical patent/JP2023541203A5/ja
Publication of JPWO2022060973A5 publication Critical patent/JPWO2022060973A5/ja
Application granted granted Critical
Publication of JP7824938B2 publication Critical patent/JP7824938B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023517268A 2020-09-16 2021-09-16 Tyk2阻害剤およびその使用 Active JP7824938B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063079217P 2020-09-16 2020-09-16
US63/079,217 2020-09-16
PCT/US2021/050649 WO2022060973A1 (en) 2020-09-16 2021-09-16 Tyk2 inhibitors and uses thereof

Publications (4)

Publication Number Publication Date
JP2023541203A JP2023541203A (ja) 2023-09-28
JP2023541203A5 JP2023541203A5 (https=) 2024-09-17
JPWO2022060973A5 JPWO2022060973A5 (https=) 2024-09-17
JP7824938B2 true JP7824938B2 (ja) 2026-03-05

Family

ID=78086111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517268A Active JP7824938B2 (ja) 2020-09-16 2021-09-16 Tyk2阻害剤およびその使用

Country Status (9)

Country Link
US (1) US20230357273A1 (https=)
EP (1) EP4214215A1 (https=)
JP (1) JP7824938B2 (https=)
KR (1) KR20230069984A (https=)
CN (1) CN117279922B (https=)
AU (1) AU2021345181A1 (https=)
CA (1) CA3192621A1 (https=)
IL (1) IL301385A (https=)
WO (1) WO2022060973A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス, インコーポレイテッド Tyk2分解剤およびそれらの使用
JP2025509596A (ja) * 2022-03-16 2025-04-11 アルミス インコーポレイテッド Tyk2阻害剤およびその使用
WO2023178235A1 (en) * 2022-03-16 2023-09-21 Alumis Inc. Tyk2 inhibitors and uses thereof
WO2023208244A1 (zh) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 大环类化合物及其应用
WO2024199479A1 (zh) 2023-03-31 2024-10-03 北京普祺医药科技股份有限公司 一种大环化合物、药物组合物及其用途
WO2024222807A1 (en) * 2023-04-27 2024-10-31 Hangzhou Highlightll Pharmaceutical Co., Ltd Novel macrocyclic heteroaryl derivatives as kinase inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018519343A (ja) 2015-07-02 2018-07-19 ティーピー・セラピューティクス・インコーポレイテッドTp Therapeutics,Inc. プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
JP2019530699A (ja) 2016-10-07 2019-10-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Il−12、il−23および/またはifnアルファ応答の調節剤として有用なイミダゾピリダジン化合物
JP2020514409A (ja) 2017-01-25 2020-05-21 ターニング・ポイント・セラピューティクス・インコーポレイテッドTurning Point Therapeutics,Inc. ジアリール大環状化合物を含む併用療法
WO2020163778A1 (en) 2019-02-07 2020-08-13 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
JP2022529311A (ja) 2019-03-26 2022-06-21 ベンティックス バイオサイエンシーズ,インク. Tyk2偽キナーゼリガンド
JP7586829B2 (ja) 2019-03-11 2024-11-19 アルミス インコーポレイテッド Tyk2阻害剤およびその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10479793B2 (en) * 2015-11-18 2019-11-19 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
CN120865208A (zh) * 2019-01-23 2025-10-31 武田药品工业株式会社 Tyk2抑制剂和其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018519343A (ja) 2015-07-02 2018-07-19 ティーピー・セラピューティクス・インコーポレイテッドTp Therapeutics,Inc. プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
JP2019530699A (ja) 2016-10-07 2019-10-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Il−12、il−23および/またはifnアルファ応答の調節剤として有用なイミダゾピリダジン化合物
JP2020514409A (ja) 2017-01-25 2020-05-21 ターニング・ポイント・セラピューティクス・インコーポレイテッドTurning Point Therapeutics,Inc. ジアリール大環状化合物を含む併用療法
WO2020163778A1 (en) 2019-02-07 2020-08-13 Ventyx Biosciences, Inc. Tyk2 pseudokinase ligands
JP7586829B2 (ja) 2019-03-11 2024-11-19 アルミス インコーポレイテッド Tyk2阻害剤およびその使用
JP2022529311A (ja) 2019-03-26 2022-06-21 ベンティックス バイオサイエンシーズ,インク. Tyk2偽キナーゼリガンド

Also Published As

Publication number Publication date
AU2021345181A9 (en) 2024-06-20
WO2022060973A1 (en) 2022-03-24
CA3192621A1 (en) 2022-03-24
AU2021345181A1 (en) 2023-05-04
IL301385A (en) 2023-05-01
JP2023541203A (ja) 2023-09-28
CN117279922A (zh) 2023-12-22
US20230357273A1 (en) 2023-11-09
KR20230069984A (ko) 2023-05-19
EP4214215A1 (en) 2023-07-26
CN117279922B (zh) 2025-12-19

Similar Documents

Publication Publication Date Title
JP7824938B2 (ja) Tyk2阻害剤およびその使用
US11731956B2 (en) Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors
JP7586829B2 (ja) Tyk2阻害剤およびその使用
JP2025509596A (ja) Tyk2阻害剤およびその使用
JP2025509594A (ja) Tyk2阻害剤およびその使用
HK40105557B (zh) Tyk2抑制剂及其用途
HK40105557A (zh) Tyk2抑制剂及其用途
RU2813233C2 (ru) Ингибиторы tyk2 и пути их применения
HK40120037B (en) Tyk2 inhibitors and uses thereof
HK40119624A (en) Tyk2 inhibitors and uses thereof
HK40120037A (en) Tyk2 inhibitors and uses thereof
HK40119624B (en) Tyk2 inhibitors and uses thereof
WO2024127363A1 (en) Tyk2 pseudokinase ligands and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260220

R150 Certificate of patent or registration of utility model

Ref document number: 7824938

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150